Semaglutide in Pakistan: real-world data

A letter published on 13 July 2026 in Diabetes, Obesity and Metabolism (PMID 42443711) responds to a 30-week Pakistani multicentre study that tracked what happened when 217 adults with type 2 diabetes started biosynthetic semaglutide in routine outpatient care^[1]. The exchange matters because the original study is one of the first prospective real-world datasets from a low-to-middle-income country on this class of drug, and the commentators add context the headline numbers alone do not capture.

The original investigation, by Hussain, Wahab, Qureshi, and colleagues, enrolled patients at several centres across Pakistan over a 30-week period^[2]. It was non-interventional: participants received whatever doses their treating clinicians prescribed under routine outpatient conditions, not a fixed protocol. The primary endpoint was change in glycated haemoglobin (HbA1c) from baseline to week 30.

What the numbers showed

HbA1c dropped from a mean of 9.27% at baseline to 7.41% at 30 weeks, a reduction of 1.86 percentage points^[2]. Three-quarters of participants (76.6%) reached an HbA1c below 8.0% by end of study; 38.7% reached below 7.0%. On body weight, the mean loss was 7.84 kg, and 76.5% of participants lost at least 5% of their starting weight.

Adverse events were predominantly non-serious and gastrointestinal, a pattern consistent with the broader GLP-1 class profile. No severe hypoglycaemic episodes were recorded across the cohort. Treatment satisfaction and physical quality of life scores both improved over the observation period.

How those figures sit against other real-world datasets

A 2026 narrative review by Bloomgarden in the Journal of Diabetes compared randomised trial evidence against real-world outcomes for incretin therapies across 26 real-world studies^[3]. In European and North American cohorts, real-world semaglutide typically produced 4.7 to 10.5 kg of weight loss over 6 to 12 months and HbA1c reductions of 1.0 to 1.3 percentage points. The Pakistan cohort's 7.84 kg and 1.86-point HbA1c reduction sit at the upper end of that band, which the commentators attribute in part to the higher baseline HbA1c (9.27%) compared with most Western datasets.

This is a well-established statistical artefact: patients with higher starting HbA1c tend to show larger absolute reductions, not necessarily because the drug works better in this population, but because there is more room to fall. Readers should hold that caveat when comparing across datasets.

What 'biosynthetic' semaglutide means here

The study uses the term biosynthetic semaglutide to distinguish the recombinant pharmaceutical product from any compounded or unverified alternative. In Pakistan, as in most markets, only the originator product holds regulatory authorisation. The EMA authorised semaglutide for type 2 diabetes in February 2018; the molecule is a GLP-1 receptor agonist produced by Novo Nordisk. For per-country regulatory status, see the semaglutide regulation pages.

The clarification matters in a resource-limited setting where grey-market analogues circulate. The Pakistan study enrolled patients on the authorised pharmaceutical product under physician supervision, which is the population the commentators are addressing^[1].

What the commentary adds

Shahid and Khan's letter (PMID 42443711) contextualises the Pakistan findings within the global type 2 diabetes burden. The WHO reported in 2023 that more than half of people living with diabetes worldwide did not take any medication for their condition in 2022, with the lowest treatment coverage in low-income settings^[4]. Against that backdrop, a 30-week real-world series showing the authorised GLP-1 agonist is workable in routine Pakistani outpatient care carries practical weight for local clinicians and health policymakers.

The commentators also flag what the study cannot answer: the 30-week observation window is short relative to the chronic course of type 2 diabetes, there is no comparator arm, and the non-interventional design means confounders were not controlled. Whether the HbA1c and weight improvements hold beyond week 30, and how long patients remain on therapy, are questions the dataset does not address.

What we do not yet know

Real-world evidence from low-to-middle-income countries on GLP-1 agonists is thin. The Pakistan multicentre study is a useful data point, but it does not tell us about longer-term persistence, dose escalation patterns in resource-limited settings, or how outcomes compare in populations with different comorbidity profiles. Cardiovascular outcomes data for semaglutide comes mainly from the SUSTAIN-6 and SELECT trials, both conducted in higher-income settings. Whether those cardiovascular benefits extend to the Pakistan outpatient population at similar rates is not established by this study.

Medical disclaimer

This article is for educational and journalistic purposes only and does not constitute medical advice. Semaglutide is a prescription medicine in most jurisdictions. Always consult a qualified healthcare professional before using any medicine. PeptideMethods.com does not sell, distribute, or facilitate the sale of any pharmaceutical product.